Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.82 |
| ▸ | SCN5A | Q14524 | 15/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.78 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.73 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.73 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4321010 | 0.88 | SCN9A (1.00) | SCN9ASCN5AKCNH2KCNQ2KCNA5 | |
| SCHEMBL13579090 | 0.87 | SCN9A (0.77) | SCN9ASCN5AKCNH2KCNQ2KCNA5 | |
| SCHEMBL3892278 | 0.86 | SCN9A (1.00) | SCN9ASCN5AKCNH2KCNQ2KCNA5 | |
| SCHEMBL3890042 | 0.86 | SCN9A (1.00) | SCN9ASCN5AKCNH2KCNQ2KCNA5 | |
| SCHEMBL4339063 | 0.85 | SCN9A (0.83) | SCN9ASCN5AKCNH2KCNQ2KCNA5 | |
| SCHEMBL4323874 | 0.85 | SCN9A (1.00) | SCN9ASCN5AKCNH2KCNQ2KCNA5 | |
| SCHEMBL4328335 | 0.85 | SCN9A (1.00) | SCN9ASCN5AKCNH2KCNQ2KCNA5 | |
| SCHEMBL4322458 | 0.85 | SCN9A (0.79) | SCN9ASCN5AKCNH2KCNQ2KCNA5 | |
| SCHEMBL4334843 | 0.85 | SCN9A (0.87) | SCN9ASCN5AKCNH2KCNQ2KCNA5 | |
| SCHEMBL3954090 | 0.85 | SCN9A (1.00) | SCN9ASCN5AKCNH2KCNQ2KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009145718-A1 | ISOINDOLINE DERIVATIVES COMPRISING AN ADDITIONAL HETEROCYCLIC GROUP AND THEIR USE IN THE TREATMENT OF PAIN DISORDERS | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | WO | disclosed |